Related content

Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy*

By Escobar P.F.   Lurain J.R.   Singh D.K.   Bozorgi K.   Fishman D.A.  

Gynecologic Oncology, Vol. 91, Iss. 3, 2003-12 ,pp. : 552-557

Elsevier

Access to resources Recommend Favorite

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)

By Mustea A.   Koensgen D.   Belau A.   Sehouli J.   Lichtenegger W.   Schneidewind L.   Sommer H.   Markmann S.   Scharf J.   Ehmke M.   Ledwon P.   Braicu I.   Zygmunt M.   Koehler G.  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 975-983

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Evaluation of 3-Day Topotecan with Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer

By Hanjani P.   Nolte S.   Shahin M.S.  

Gynecologic Oncology, Vol. 85, Iss. 2, 2002-05 ,pp. : 278-284

Academic Press

Access to resources Recommend Favorite

A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer

By Esteban E.  

Breast Cancer Research and Treatment, Vol. 62, Iss. 2, 2000-07 ,pp. : 127-133

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases

By Gruschow K.   Klautke G.   Fietkau R.  

European Journal of Cancer, Vol. 38, Iss. 3, 2002-01 ,pp. : 367-374

Elsevier

Access to resources Recommend Favorite